This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
by Zacks Equity Research
Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
BMYPositive Net Change AMGNNegative Net Change GILDNegative Net Change RGNXNegative Net Change MORPositive Net Change
biotechnology biotechs pharmaceuticals
Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted
by Zacks Equity Research
Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.
BMYPositive Net Change MRKNegative Net Change IMGNPositive Net Change PBYINegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
BIIBNegative Net Change MRNAPositive Net Change
biotechs
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
by Zacks Equity Research
REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.
IMGNPositive Net Change PBYINegative Net Change RGNXNegative Net Change IMCRPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury
by Zacks Equity Research
Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.
GSKPositive Net Change GILDNegative Net Change SRPTNegative Net Change PBYINegative Net Change
biotechnology biotechs pharmaceuticals
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
by Zacks Equity Research
Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
EXELPositive Net Change SRPTNegative Net Change PBYINegative Net Change RCUSPositive Net Change
biotechnology biotechs pharmaceuticals
Amgen (AMGN) Q4 Earnings Top, Horizon Drugs Drive Sales
by Zacks Equity Research
Amgen (AMGN) beats fourth-quarter estimates for earnings and sales. Horizon's products add $954 million in sales in the quarter.
AZNNegative Net Change NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
by Zacks Equity Research
Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.
PBYINegative Net Change IMNMNegative Net Change IMCRPositive Net Change
biotechs
Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.
IMGNPositive Net Change PBYINegative Net Change DCPHPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug
by Zacks Equity Research
Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.
NVSPositive Net Change INCYPositive Net Change ABBVNegative Net Change MORPositive Net Change
biotechnology biotechs pharmaceuticals
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
by Zacks Equity Research
Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
NVSPositive Net Change BMYPositive Net Change PBYINegative Net Change
biotechnology biotechs pharmaceuticals
Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.
VRTXPositive Net Change PBYINegative Net Change CRSPNegative Net Change KODNegative Net Change
biotechs earnings
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
by Zacks Equity Research
Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.
NVOPositive Net Change PBYINegative Net Change DERMPositive Net Change CTLTPositive Net Change
biotechnology biotechs pharmaceuticals
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More
by Zacks Equity Research
Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
LLYNegative Net Change AMGNNegative Net Change GILDNegative Net Change EXELPositive Net Change
biotechs medical
Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
by Zacks Equity Research
AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
JNJPositive Net Change AMGNNegative Net Change ABBVNegative Net Change SDZNYPositive Net Change
biotechs medical pharmaceuticals
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
by Zacks Equity Research
Per the deal, Protagonist (PTGX) will grant exclusive rights to Takeda to market its late-stage rare hematology drug. In return, Takeda will make an upfront payment of $300 million.
SRPTNegative Net Change AVXLNegative Net Change PTGXPositive Net Change TAKNegative Net Change
biotechs medical
Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains
by Zacks Equity Research
Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.
BMYPositive Net Change PFEPositive Net Change NVOPositive Net Change SRPTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its lead drug, Trikafta/Kaftrio, and progress with other pipeline candidates.
VRTXPositive Net Change SRPTNegative Net Change CRSPNegative Net Change
biotechs
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.
GILDNegative Net Change MRNAPositive Net Change NTLAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
by Zacks Equity Research
Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.
REGNNegative Net Change RHHBYPositive Net Change NVOPositive Net Change SRPTNegative Net Change
biotechs earnings pharmaceuticals
Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.
AZNNegative Net Change NVOPositive Net Change MRKNegative Net Change HARPNegative Net Change
biotechs earnings medical pharmaceuticals
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
by Zacks Equity Research
TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
SNYNegative Net Change TEVANegative Net Change PBYINegative Net Change KODNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
by Zacks Equity Research
Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.
BIIBNegative Net Change PBYINegative Net Change KODNegative Net Change RPTXPositive Net Change
biotechs
Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal
by Zacks Equity Research
Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.
REGNNegative Net Change GSKPositive Net Change BIIBNegative Net Change VRTXPositive Net Change
biotechnology biotechs pharmaceuticals